Market Overview

AbbVie Acquires Mavupharma For Undisclosed Amount


AbbVie (NYSE: ABBV) said Monday it acquired Seattle-based biopharmaceutical company Mavupharma for an undisclosed amount.

Mavupharma is focused on approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.

"AbbVie's vision in oncology is to advance breakthrough areas of science leading to a strong pipeline of innovative cancer therapies," said Steve Davidsen, AbbVie's vice president of oncology discovery. "Mavupharma's platform has the potential to further our immuno-oncology portfolio and assist in the development of transformative medicines for patients."

AbbVie shares are around $70.28 on Monday. The stock has a 52-week high of $100.23 and a 52-week low of $65.06.

Related Links:

AbbVie To Acquire Allergan In $63B Deal

Callon Petroleum To Acquire Carrizo In All Stock Deal

Posted-In: M&A News


Related Articles (ABBV)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

An ETF Industry Goliath Could Enter Cannabis ETF Competition

Organigram Falls Despite Q3 Revenue Growth